It seems the path to commercialization of Vivagel has turned out much more difficult/complicated that SPL Management had anticipated. Let's face it, why have they been unable to line up a European partner for the past 2-3 years? The whole talk about the product will be more attractive to a potential partner if it addresses both prevention and cure is just pure garbage. There is such a thing called label expansion in the pharma world. Then they announce with great fanfare that they hired the services of a US based life and sciences investment bank to conduct global licensing negotiations. Cause Australia has no investment banking firm with global reach? By the way, management has still not divulged the identity of the IB shop... When was that announcement again? How long does it take to find a dancing partner for a product that has all the appearances of a USD250 Millions to USD 1 Billion a year global franchise? I can give examples of various pharmaceutical startups that secured lucrative licensing deals right after phase 2. The latest tune from management is that the launch date for Fleurstat was rescheduled from late 2017 to some time in 2018???? My question: is the current management adequately equipped/skilled to transition this company from a research focused organization to a commercially focused organization. That remains to be seen.
SPL Price at posting:
$1.18 Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)